[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516873":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":18,"locations":26,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"First Affiliated Hospital Xi'an Jiaotong University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Myocarditis group",null,"All enrolled patients are administered antiviral drugs, glucocorticoids, immunoglobulins, and other standard treatments. Additionally, the decision to provide ECMO support therapy is based on the severity of the patient's condition.",[13,16],{"name":14,"affiliation":5,"role":15},"Yang Yan","PRINCIPAL_INVESTIGATOR",{"name":17,"affiliation":5,"role":15},"Guoliang Li",[19,23],{"name":17,"role":20,"phone":21,"phoneExt":10,"email":22},"CONTACT","+8613759982523","liguoliang_med@163.com",{"name":14,"role":20,"phone":24,"phoneExt":10,"email":25},"+8613259882601","yangyan3@xjtu.edu.cn",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"First Affiliated Hospital of Xi'an Jiaotong University","RECRUITING","Xi'an","Shaanxi","710061","China","CN",{"type":36,"coordinates":37},"Point",[38,39],108.92861,34.25833,{"lat":39,"lon":38},[42,43],{"name":17,"role":20,"phone":10,"phoneExt":10,"email":22},{"name":14,"role":20,"phone":44,"phoneExt":10,"email":25},"+862985323865",{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100516873","risk-stratification-value-of-biomarkers-in-patients-with-myocarditis-100516873",false,"NCT06010199","Risk Stratification Value of Biomarkers in Patients With Myocarditis","Risk Stratification Value of Biomarkers in Patients With Myocarditis (FORWARD): a National, Multicenter, Retrospective-prospective, Cohort Study","FORWARD","Inclusion Criteria:\n\n* All patients should meet the diagnostic criteria for myocarditis\n* Patients who are regularly followed up at the corresponding cardiovascular center\n\nExclusion Criteria:\n\n* Age \\\u003C3 years or \\>80 years\n* Pregnant or lactating women\n* The patient refused to sign the informed consent and refused to participate in the study\n* None of the above is consistent, but the patient cannot sign the informed consent temporarily due to coma and other reasons, and there is no legal representative to sign it instead. Depending on the condition, the patient may not wake up to sign the informed consent","ALL","3 Years","80 Years",{"count":59,"type":60},1000,"ESTIMATED","OBSERVATIONAL","The aim of this study is to collect clinical data and biological specimens from patients with myocarditis and construct a predictive model for the prognosis of myocarditis.",[64],"Myocarditis",[64,66,67],"Biomarker","Risk stratification","2024-07-10",{"date":70,"type":71},"2024-07-12","ACTUAL",{"date":73,"type":71},"2023-08-25",{"date":75,"type":60},"2030-08-31",{"name":5,"class":6},1]